About Abide Therapeutics
Abide Therapeutics is a Healthcare company based in San Diego (United States) founded in 2011, and was acquired by Lundbeck in May 2019. Serine hydrolase inhibitors are developed for pain management. Abide Therapeutics has raised $12.2 million across 2 funding rounds from investors including Lundbeck and Cardinal Partners. The company has 47 employees. Its focus areas include Life Sciences, Pain Management, Drugs and Diversified. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Abide Therapeutics investigates serine hydrolase inhibitors for pain management. It uses a proprietary drug development platform to generate lead molecules for inhibition of serine hydrolase activity. Its lead candidate targets monoacylglycerol lipase, a type of serine hydrolase, in the endocannabinoid system. It mimics the analgesic effects of marijuana without affecting cognition and is currently in phase I clinical trials.
- Headquarters San Diego, United States
- Employees 47
- Stage Acquired
- SectorsHealthcare
- Website abidetx.com
- Social LinkedIn X
- Acquired by Lundbeck (May 2019)
Funding Insights of Abide Therapeutics
Abide Therapeutics has successfully raised a total of $12.2M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.2M
- Total Rounds 2
- Last Round Series B β $10M
- First Round $2.2M
(Nov 2011)
- Investors Count 1
All 2 funding rounds of Abide Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2014 | $10M | Series B | β | β | |
| Nov 2011 | $2.2M | Seed | β | β | β |
2 investors in total: 2 institutional.
Investors in Abide Therapeutics
Abide Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Lundbeck and Cardinal Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science & tech focused VC firm investing in early stage companies in the US | cardinalpartners.com | Princeton, United States | ||
Drugs for CNS disorders are developed and advanced. | 1915 | lundbeck.com | Copenhagen, Denmark |
Investor details for Abide Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Abide Therapeutics
4 dated milestones of Abide Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Abide Therapeutics is founded.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Series B, of $10.0M.
- Exit Acquired by Lundbeck.
Competitors of Abide Therapeutics
Abide Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. |
Detailed competitors of Abide Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Abide Therapeutics
The website of Abide Therapeutics (abidetx.com) receives about 3.1K visits a month.
- Monthly visits3.1K
▲ 932.6% vs previous month
Top companies in Pain Management
3 companies that operate in the same segment as Abide Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abide Therapeutics
Complete news archive for Abide Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abide Therapeutics
Abide Therapeutics was founded in 2011.
Abide Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Abide Therapeutics is a funded company, having raised a total of $12.2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.2M, raised on Nov 2011.
Abide Therapeutics has 47 employees.
Abide Therapeutics investigates serine hydrolase inhibitors for pain management. It uses a proprietary drug development platform to generate lead molecules for inhibition of serine hydrolase activity. Its lead candidate targets monoacylglycerol lipase, a type of serine hydrolase, in the endocannabinoid system. It mimics the analgesic effects of marijuana without affecting cognition and is currently in phase I clinical trials.
Abide Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
Abide Therapeutics has 2 investors. Key investors include Lundbeck, and Cardinal Partners.
Yes. Abide Therapeutics was acquired by Lundbeck in May 2019.

